Taiho Oncology, Inc.
Registry sponsor category
Industry
- Company name
- Taiho Oncology, Inc.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Taiho Oncology
- Taiho Oncology, Inc.
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (86)
- A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
- A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
- A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
- A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
- A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
- A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
- A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
- A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1
- A Safety and Efficacy Study in Patients With Gastric Cancer
- A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
- A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
- A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- A Study of ARC-02 in B-cell NHL
- A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
- A Study of TAS-116 in Patients With Solid Tumors
- A Study of TAS-120 in Patients With Advanced Solid Tumors
- A Study of TAS-120 in Patients With Metastatic Breast Cancer
- A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer